Drug intelligence / Profile preview

MK-2748

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-2748 is an investigational small molecule drug developed by Merck & Co for the treatment of hepatitis C virus (HCV) infection. It acts as a potent inhibitor of the HCV NS3/4A protease, targeting a broad range of genotypes and clinically relevant mutant viruses. The compound was designed to optimize cross-genotype potency and pharmacokinetic properties, with oral administration as its intended route. Clinical development reached Phase 1 trials in patients with genotype 1 and genotype 3 HCV infection[2][3][4][5][7].

Other names: UNII-7YM030A71CUNII7YM030A71CUNII 7YM030A71C1193902-95-2

Targets

NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)

Beyond the preview

Go deeper on MK-2748.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-2748.

Explore the full profile